Overview

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms

Status:
Completed

Trial end date:
2005-10-01

Target enrollment:

Participant gender:

Summary

Prospective, double-blind, double-randomised, 2-arm parallel group study. Optimal dose increase. Primary efficacy assessment of OAB symptoms by patient diaries.

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Solifenacin Succinate